Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ENHANCED ANTITUMOR EFFICACY IN MICE BY COMBINATION TREATMENT WITH INTERLEUKIN-1-ALPHA AND INTERFERON-ALPHA
Autore:
BRUNDA MJ; WRIGHT RB; LUISTRO L; HARBISON ML; ANDERSON TD; MCINTYRE KW;
Indirizzi:
HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT ONCOL,340 KINGSLAND ST NUTLEY NJ 07110 HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT TOXICOL & PATHOL NUTLEY NJ 07110 HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT IMMUNOPHARMACOL NUTLEY NJ 07110
Titolo Testata:
Journal of immunotherapy with emphasis on tumor immunology
fascicolo: 4, volume: 15, anno: 1994,
pagine: 233 - 241
SICI:
1067-5582(1994)15:4<233:EAEIMB>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; RECOMBINANT HUMAN INTERLEUKIN-1-ALPHA; LEWIS LUNG-CARCINOMA; KILLER CELL-ACTIVITY; MELANOMA-CELLS; CYTOKINES; INVITRO; GROWTH; INVIVO; GAMMA;
Keywords:
INTERLEUKIN-1; INTERFERON ALPHA; ANTITUMOR ACTIVITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
35
Recensione:
Indirizzi per estratti:
Citazione:
M.J. Brunda et al., "ENHANCED ANTITUMOR EFFICACY IN MICE BY COMBINATION TREATMENT WITH INTERLEUKIN-1-ALPHA AND INTERFERON-ALPHA", Journal of immunotherapy with emphasis on tumor immunology, 15(4), 1994, pp. 233-241

Abstract

The antitumor efficacy of recombinant murine interleukin-1 alpha (rMuIL-1 alpha) was evaluated either alone or in combination with recombinant human hybrid interferon alpha A/D (IFN-alpha A/D) against the murine B16F10 malignant melanoma. Treatment of subcutaneous tumor-bearing mice intraperitoneally with rMIL-1 alpha resulted in a dose-dependent inhibition of tumor growth with the greatest activity obtained with the maximum tolerated dose of rMuIL-1 alpha (10 mu g per treatment). Augmented tumor inhibition comparable to that seen in mice treated with ahigh dose of rMuIL-1 alpha was observed in subcutaneous tumor-bearingmice injected with the combination of IFN-alpha A/D and a low dose ofrMuIL-1 alpha. Similar inhibition of subcutaneous tumor growth was obtained in T-cell-deficient nude or natural killer cell-deficient beigemice. In contrast, treatment of mice bearing B16F10 experimental pulmonary metastases with rMuIL-1 alpha resulted in no decrease in the number of metastases, and rMuIL-1 alpha did not potentiate the antimetastatic activity of IFN-alpha A/D. A synergistic induction of IL-6 was induced in mice treated with the combination of rMuIL-1 alpha plus IFN-alpha A/D but the level of IL-6 induced was not correlated with inhibition of tumor growth because this elevation of IL-6 was not observed intumor-bearing nude mice. No direct antiproliferative activity was demonstrable in vitro against B16F10 cells with rMuIL-1 alpha, IL-6, or rMuIL-1 alpha plus IL-6, and addition of these cytokines did not enhance the antiproliferative activity of IFN-alpha A/D, These results indicate that after parenteral administration the combination of rMuIL-1 alpha plus IFN-alpha A/D has enhanced antitumor efficacy relative to either cytokine alone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 09:42:11